Author: Johnson Francis

Rivaroxaban is an anticoagulant that acts by selective direct inhibition of factor Xa. It is the latest oral anticoagulant to be approved by US FDA, after dabigatran.

Neurodevelopmental problems post d-TGA repair Children who would never have survived to adulthood due to D-transposition of great arteries are now able to grow well into adulthood, thanks

Plaque rupture and ulceration common in females with myocardial infarction and non obstructed coronaries

Abnormal heart rate recovery after exercise predicts mortality. Abnormal heart rate recovery after cardiac rehabilitation predicts higher mortality.

Tecarfarin is a vitamin K analogue which acts by inhibiting vitamin K epoxide reductase.

Apixaban is a direct factor Xa inhibitor. It has an oral bioavailability of about fifty percent.

Rivaroxaban is direct, specific, competitive factor Xa inhibitor and it has a half life of five to thirteen hours.

Multidetector CT was performed immediately after the final check angio of PCI procedure without administering any further contrast for the CT.

Good correlation between IVUS derived measurements and 3D quantitative coronary angiography has been demonstrated in a study.

Carotid artery stenting for acute atherosclerotic occlusion of extracranial portion of internal carotid artery with a severe stroke is feasible and safe.